Leukemia, Myelodysplasia, Transplantation
News
Algorithm uncovers DS in AML patients on IDH inhibitors
SAN DIEGO—An algorithm has proven effective for identifying differentiation syndrome (DS) in patients taking ivosidenib or enasidenib, according...
News
Dasatinib re-challenge feasible as 2nd attempt at TKI discontinuation
SAN DIEGO—Preliminary trial results suggest re-treatment with dasatinib is feasible and safe for a second attempt at tyrosine kinase inhibitor (...
Clinical Review
Myelodysplastic Syndromes
Clinical Review
Diagnosis and Management of Acute and Chronic Graft-versus-Host Disease
News
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Clinical Review
Post-transplant Lymphoproliferative Disorders
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Clinical Review
Chronic Lymphocytic Leukemia
News
ALL regimens clear disease in kids with MPAL
SAN DIEGO—Pediatric patients with mixed phenotype acute leukemia (MPAL) can achieve minimal residual disease (MRD) negativity with acute...
Video
FLT3 inhibitor moves forward in newly diagnosed AML
SAN DIEGO – Dr. Keith W. Pratz reviewed results from a phase 1 study of gilteritinib and next steps in newly diagnosed patients.
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...